Blood serum peptidases in patients with ovarian carcinoma treated with Ledakrin.
The authors observed changes in activity of leucine amino-peptidase (E.C. 3.4.1.1--LAP), gamma-glutamyl transpeptidase (F.C 2.3.2.2--GGTP) and Co++-activated acylase in blood serum of patients with ovarian carcinoma, with or without ascites, treated with Ledakrin (1-nitro-9-[3-dimethylaminopropylamino] acridine). It was stated that the activities of LAP and GGTP increased during the treatment and during tumor progression. The level of Co++-activated acylase increased only slightly during the treatment and therefore, the determination of this enzyme appeared to be of no use in monitoring the therapy of ovarian carcinoma.
D000166:Acridines / Q000494:pharmacology*; D000581:Amidohydrolases / Q000097:blood; D001201:Ascites / Q000097:blood / Q000201:enzymology; D003035:Cobalt; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007931:Leucyl Aminopeptidase / Q000097:blood; D008099:Liver / Q000187:drug effects; D009564:Nitracrine / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D005723:gamma-Glutamyltransferase / Q000097:blood
D000166:Acridines; D003035:Cobalt; D009564:Nitracrine; D005723:gamma-Glutamyltransferase; D007931:Leucyl Aminopeptidase; D000581:Amidohydrolases